Recursive Adaptation
Article
Recursive Adaptation is a recurring organization in the Astral Codex Ten archive, appearing 2 times across 2 issues between December 17, 2024 and March 12, 2025. The archive places it in contexts such as “Nicholas Reville of Recursive Adaptation”; “thanks to Recursive Adaptation for their article on this strategy”. It most often appears alongside FDA, Trump, 2016 US Presidential election.
Metadata
- Category: Organizations
- Mention count: 2
- Issue count: 2
- First seen: December 17, 2024
- Last seen: March 12, 2025
Appears In
Related Pages
-
- FDA (2 shared issues)
-
- Trump (2 shared issues)
-
- 2016 US Presidential election (1 shared issues)
-
- ACX Grant (1 shared issues)
-
- AI (1 shared issues)
-
- AI Art Turing Test (1 shared issues)
-
- Aleister Crowley (1 shared issues)
-
- Alfredo Parra (1 shared issues)
-
- Andreesen (1 shared issues)
-
- anime (1 shared issues)
-
- Archbishop of Canterbury (1 shared issues)
-
- Aristotle (1 shared issues)
External Links
Source Context
Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.
52: Nicholas Reville of Recursive Adaptation has published his Innovation Agenda For Addiction, sort of the Progress Studies-ish take on the opioid crisis and how to solve it. The main points are deploying GLP-1RAs for their anti-addictive effects, giving addiction medicines a special fast-track through the FDA, and various government incentives / advance purchase commitments / partnerships. Even aside from the plan, this is interesting to read for its examination of perverse incentives in medicine - for example, pharma companies are reluctant to develop anti-addiction medications because they don't want to be seen as "profiting off a crisis", and they don't want to study their existing medications for addiction because the studies might reveal new side effects that would harm their existing business. Everything here seems reasonable, but my main worry is that a lot of it is zero-sum - the FDA only has so much review capacity, spending it on addiction meds would decrease it for other meds, and I worry that every disease is so bad that "redirect the FDA to focus on this in particular!" sounds pretty good when you think about it on its own. I am more excited about finding ways to streamline it in general - but don't begrudge advocates for particular conditions for wishing they had an easier time.
Inline links: Innovation Agenda For Addiction
Compounding pharmacies are allowed to provide patients with drugs formulated for unusual routes of administration. All of our patients just developed severe needle phobia, sorry, so they need semaglutide gummies. Since the pharma companies don’t make semaglutide gummies, it has to be compounded and we can still sell it (thanks to Recursive Adaptation for their article on this strategy).
Inline links: Recursive Adaptation